◆ NeutralSPRY

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

GlobeNewswire Inc.·
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP announced a securities fraud class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for making false and misleading statements regarding timeline issues related to CVS Caremark's addition of neffy to its formulary. The class period spans March 9, 2026 to June 24, 2026, with an October 5, 2026 deadline for investors to participate. Shareholders who suffered losses are encouraged to contact the firm regarding lead plaintiff appointments.

Read Full Article at GlobeNewswire Inc.
← Back to Financial Intelligence